Abstract OBJECTIVE: To compare the efficacy of valproic acid (VPA) and lamotrigine as a monotherapy for absence epilepsy in children.MethodsA randomized, open-label design was used. Childhood absence epilepsy was diagnosed based on the presence of typical seizures and video-EEG findings. Eligible patients were randomly treated with VPA or lamotrigine. All patients were followed up for 12 months. RESULTS: Forty-five out of 48 eligible children completed the study. There were 23 children in the VPA group and 22 children in the lamotrigine group. Seventeen children were seizure-free in the VPA group 12 months after treatment. Fifteen out of the 17 children showed normal EEG (no epileptic-formed discharge). Twelve children were seizure-free in the lamotrigine group 12 months after treatment. The proportion showing normal EEG in the camotrigine group (6/22, 27.3%) was significantly lower than that in the VPA group (15/23, 65.2%) (P<0.05). Severe adverse effects were not found in both groups. CONCLUSIONS: Both VPA and lamotrigine are safe and efficacious for treatment of absence seizures in children. VPA appears to be better than lamotrigine in tapering epileptic-formed discharge.［Chin J Contemp Pediatr, 2009, 11 (8):653-655］
HUANG Tie-Shuan,ZHU Jin-Lan,LI Bing et al. Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children[J]. 中国当代儿科杂志, 2009, 11(08): 653-655.
HUANG Tie-Shuan,ZHU Jin-Lan,LI Bing et al. Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children[J]. CJCP, 2009, 11(08): 653-655.
［6］Biton V, Levisohn P, Hoyler S, Vuong A, Hammer AE. Lamotrigine versus valproate monotherapy—associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, doubleblind clinical trial［J］. J Child Neurol, 2003, 18(2):133-139.
［7］Morrell MJ, Hayes FJ, Sluss PM, Adams JM, Bhatt M, Ozkara C, et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine［J］. Ann Neurol, 2008, 64(2):200-211.
［8］Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children［J］. Epilepsia, 1999, 40(7):985-991.
